An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
H3 Biomedicine, Inc.
Start Date
February 5, 2018
End Date
May 20, 2021
Administered By
Duke Cancer Institute
Awarded By
H3 Biomedicine, Inc.
Start Date
February 5, 2018
End Date
May 20, 2021